Global Access Program - HIV

Working hand in hand

Providing innovative HIV/AIDS diagnostic solutions to those you need it most

More than 35 million people are currently living with HIV

Universal access to quality healthcare and medical innovation remains a global challenge. To address this challenge, many of the world’s top relief and aid organizations have joined together with an ambitious goal: ending the HIV/AIDS pandemic.

As the leading provider of HIV viral load testing, Roche created the Global Access Program to contribute to the UNAIDS 90-90-90 goal, expanding access to quality, sustainable diagnostic testing for countries hardest hit by HIV.

Working hand in hand to provide innovative diagnostic solutions to those who need it mos

"We applaud all the global partners who came together to ensure that over 31 million people living with HIV/AIDS in low- and middle-income countries will be able to access viral load testing at this reduced price."


President Bill Clinton, Chairman of the Clinton Health Access Initiative

"We welcome this significant price breakthrough – the urgent call of people living with HIV is being answered. Now, with viral load testing, we can help ensure HIV treatment improves quality of life."


Michel Sidibé, UNAIDS Executive Director


Innovation in HIV testing

Redefine the reach of reliable testing. Making quantitative HIV viral load testing more accessible to those in remote areas.1   


95-95-95 lays the groundwork for achieving global HIV viral suppression


By 2030...


of people living with HIV will know their HIV status


of people who know their status recieve treatment


of people on HIV treatment have a surpressed viral load


95-95-95 aims to put an end to the AIDS epidemic by 2030.2

Targeting 95-95-95 with optimized diagnostic testing


The Global Access Program contributes to the goals of 95-95-95 by providing diagnostic products for early infant diagnosis and viral load testing.


Early Infant Diagnosis

Early diagnosis in infants and young children is a major challenge—antibody tests are ineffective due to maternal antibodies remaining in the child. The Roche HIV-1/HIV-2 Qualitative Assay provides reliable, accurate information on whether or not an infant is infected.3

RMD_Virology_Early Infant Diagnostics

Dry blood spot

The use of dried blood spots is an increasingly sustainable solution which allows for PCR testing. Collecting a small blood sample on a specially designed collection card facilitates easy sample transportation and storage, and is ideal for resource-limited areas.3


The number of children younger than 15 recieving life-saving antiretroviral therapy (ART) gloally increased from 435,000 in 2010 to 948,000 in 2019.4

pregnant woman

85% of pregnant women living with HIV had access to antiretroviral medicines to prevent transmission of HIV to their child in 2019.5


Expansion of Prevent-Mother-toChild Transmission (PMTCT) programs have helped avoid approximately 1.4 million new HIV infections among children between 2010 and 2018. 6


From 2010 to 2016 the number of children aged 0-14 years dying of AIDS-related illnesses was nearly cut in half in just six years.7

Learn more about the critical importance of early infant diagnosis.

Viral Load Testing

Roche is a global market leader in HIV viral load testing, a method for determining the amount of HIV circulating in a body. Testing for viral load can confirm if patients are responding to medication, or if second-line therapies should be considered.

African Woman


increase in access to antiretroviral therapy since 2002.8

33% decrease

in new HIV infections since 2001.8


Additional Global Access Program HIV Information

HIV Mobile Health Application

With the expansion of antiretroviral treatment (ART) programs, the need to keep patients engaged in care over time is critical to attain and sustain HIV elimination goals.  The HIV m-Health app supports HIV-positive adults by delivering results for viral load testing directly into their smartphones and supports Early Infant Diagnosis for HIV-exposed infants by sending notifications to their caregivers that diagnostic test results are available. 


Our partners




UNAIDS is working to end the AIDS epidemic by 2030.

Learn More

Clinton Health Access Initiative

CHAI was founded to help the lives of millions of people living with HIV/AIDS in the developing world.

Learn more

The Global Fund


Accelerating the end of AIDS, tuberculosis, and malaria as epidemics.

Learn More
  1. Carmona S, Seiverth B, Magubane D. Separation of plasma from whole blood by use of the cobas plasma separation card: a compelling alternative to dried blood spots for quantification of HIV-1 viral load.
  2. Understanding Fast-Track. Accelerating Action to End the AIDS Epidemic by 2030. UNAIDS. Accessed 4 Feb 2021.
  3. Mazanderani AH, Moyo F,Kufa T et al. Differentiating clearly positive from intermediate results: A review of irreducible HIV-1 PCR positive samples from South Africa’s early infant diagnostic program, 2010-2015. Diagnostic Microbiol and Infectious disease. 018. 91;3:248-255.
  7. (pg. 23)
  8. UNAIDS 2013 | AIDS by the Accessed June 13, 2016.